Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor, Inc. (NYSE: AVTR) will release its third quarter 2021 financial results on October 28, 2021, after market close. A conference call to discuss the results is scheduled for October 29, 2021, at 7:30 a.m. EDT. Interested parties can join by phone or listen to a live webcast via the investors section of our website. The earnings press release will be available on the company’s website.
Avantor announced the pricing of an underwritten offering of 20,833,334 shares of its common stock at $42.00 per share. The offering includes a 30-day option for underwriters to purchase an additional 2,976,190 shares. Proceeds will primarily finance the acquisition of Masterflex from Antylia Scientific and may also support general corporate purposes. The offering is set to close on September 16, 2021, pending customary conditions. Goldman Sachs, Citigroup, and BofA Securities are among the joint book-running managers for this transaction.
Avantor announced plans to offer $750 million of common stock in an underwritten offering, related to a pending acquisition of the Masterflex bioprocessing business. The proceeds will also support debt financing. Underwriters may purchase additional shares within 30 days. The company aims to use net proceeds primarily for the acquisition, or for general corporate purposes if not completed. The offering's managers include Goldman Sachs, Citigroup, and BofA Securities.
Avantor, Inc. (NYSE: AVTR) announced a definitive agreement to acquire Masterflex bioprocessing business from Antylia Scientific for $2.9 billion, netting $2.7 billion after tax benefits. Masterflex, based in Illinois, focuses on peristaltic pumps and single-use fluid transfer technologies, generating approximately $300 million in estimated 2022 revenues. This acquisition aims to enhance Avantor's biopharma offerings, contributing to revenue growth and margin improvement. Completion is expected in Q4 2021, subject to regulatory approvals.
Avantor, Inc. (NYSE: AVTR) announced a multi-year investment to enhance its global hydration capabilities, completing a significant facility expansion in Gliwice, Poland, and initiating further expansion in Aurora, Ohio, projected to finish by mid-2022. This investment aims to support the biopharmaceutical industry's increasing demand for biologics by outsourcing buffer preparation, which can streamline workflows and accelerate therapy production. The expanded facilities will improve Avantor's ability to offer WFI-quality water buffer manufacturing, enhancing support for biopharma manufacturers globally.
Avantor, a global leader in mission-critical products for various industries, announced a virtual investor day scheduled for September 9, 2021, at 9:00 a.m. EDT. The event will be accessible via webcast on their official website, where a replay will also be available post-event. Avantor serves over 225,000 customer locations globally, impacting research and production across biopharma, healthcare, education, and advanced technology sectors. The company emphasizes forward-looking statements, cautioning that these may involve risks and uncertainties.
Avantor, Inc. (NYSE: AVTR) reported robust financial results for Q2 2021, with net sales of $1.86 billion, up 25.7% year-on-year. Net income surged 162.1% to $157.8 million. The company achieved 34.2% growth in Adjusted EBITDA to $366.6 million, with a margin expansion of 125 basis points. Despite two acquisitions, Ritter GMBH and RIM Bio, having no significant impact on quarterly results, the company raised its full-year guidance, reflecting confidence in ongoing momentum across various markets.
Summary not available.
Avantor (NYSE: AVTR) announced a quarterly cash dividend of $0.78 per share for its 6.250% Series A Mandatory Convertible Preferred Stock, translating to a rate of 1.560%. This dividend is payable on August 16, 2021 to shareholders of record as of August 1, 2021. As a leading global provider of essential products and services across life sciences and technology sectors, Avantor's substantial footprint serves over 225,000 customer locations in more than 180 countries, underscoring its influence in critical research and development activities.
Avantor, Inc. (NYSE: AVTR) has announced a change in the schedule for its second quarter 2021 earnings release. The financial results will now be disclosed after market close on July 29, 2021, followed by a conference call on July 30, 2021, at 7:30 a.m. EDT. Interested participants can join the call by dialing (866) 211-4132 domestically or (647) 689-6615 internationally. A live webcast will be available on the company’s investor webpage, with a replay accessible until August 28, 2021.